Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
about
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the futureEAACI Molecular Allergology User's Guide.Flexible IgE epitope containing domains of Phl p 5 cause high allergenic activity.Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence.Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.Identification of IgE-binding peptide and critical amino acids of Jatropha curcas allergen involved in allergenic responseImmunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B InfectionMechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergyA B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help.Advances in allergen immunotherapy: aiming for complete tolerance to allergens.Allergen extracts for immunotherapy: to mix or not to mix?Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES.The adaptive immune system in atopic dermatitis and implications on therapy.Grass pollen immunotherapy: where are we now.Navigating through the Jungle of Allergens: Features and Applications of Allergen Databases.Pros and Cons of Clinical Basophil Testing (BAT).Novel approaches and perspectives in allergen immunotherapy.Molecular aspects of allergens in atopic dermatitisUtility and Comparative Efficacy of Recombinant Allergens Versus Allergen Extract.Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens.Hypoallergenic Variant of the Major Egg White Allergen Gal d 1 Produced by Disruption of Cysteine Bridges.Clustering of conformational IgE epitopes on the major dog allergen Can f 1.The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune FunctionsTherapeutic vaccines for allergic disease.Similar localization of conformational IgE epitopes on the house dust mite allergens Der p 5 and Der p 21 despite limited IgE-cross-reactivity.Nano-liposome-based target toxicity machine: an alternative/complementary approach in atopic diseases.Perspectives in allergen immunotherapy: 2017 and beyond.Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.[Innovative forms of specific immunotherapy].Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze.Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases.Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition
P2860
Q26768511-A21F3386-8497-45F8-844A-DAD7B066D3F1Q30276634-1D69A907-DEA0-4507-9F4A-DC9796438CD0Q30402299-9B172165-4403-43B2-BC99-335CD37ED434Q33802263-9C42B3B8-F8EF-491A-AD6C-F17FE16B6F3CQ36565528-F9AD9FFE-4BF6-4948-8460-13F7922A9E3BQ36798819-2E864D18-99BF-4342-BBDB-95F832C52324Q37309327-1F6E500E-3DC2-477F-A62B-FADA6D241507Q37309704-D5581679-624E-4621-B6E9-AF08B6767191Q37625474-FBBD6C63-460F-4EA0-B9C9-4C7D5F6B423FQ38391526-91EC130E-EB30-45B0-AA1F-4250FE0D21BCQ38664847-E9563980-7093-460B-99FC-C2DF139A6AFEQ38760754-0A3345A1-889F-40A4-918C-18D7FD349BB7Q38769936-74D7E8D2-A74D-4027-9DA9-E52839929B20Q38773340-7795939D-E4CC-475D-AA79-52550F7F6BB6Q38812628-9FDF2EEC-AF8F-4356-80CD-89D9F730F1DEQ38895325-C7974FE6-B60B-4243-A766-4C7F7F5031DEQ39103046-6BF748DA-C519-4560-93CC-5797D62C3F9BQ39378515-91E44CE1-0F5C-4C2E-86EC-EBE0EE70F4E0Q40087434-2F9B2941-BBBB-4830-9524-C21BC9755F45Q41196294-25EEFFB0-6F4C-400C-A32F-9D97804FF3BDQ41812197-7769998C-9555-47FF-A31C-5780369C2A53Q42252694-B9A5A044-7D9D-4B3F-902B-BDF0C86CC1B7Q42335943-18F94841-6D0D-4F98-A58D-FE238DF5046DQ47100584-3D5B685D-0F49-43B4-8DD9-497F08483B55Q47214140-C65EF718-7D81-4DFB-A267-B5ECED4DE04DQ47254471-A392EE75-3D08-41D3-A1D3-312B2090EB8AQ47700986-2734366F-8B50-4688-BF50-4FC3B158C3C9Q50119865-0E16F122-3326-4AB5-8986-07754F116C90Q53505747-60AB3CC0-98DB-45E1-80AF-41C9579543E4Q55277398-438648AE-EE8C-4E77-B064-926415628587Q55435487-76934457-A321-4379-A172-A90638F56544Q55436442-35C5441B-6B5B-4C3C-A68A-E807A8C30274Q55693712-D00ED1B8-28CC-4DE3-89E3-E6A5E29DF1EFQ58700268-16D54023-40EF-450C-A5F8-DE656C32260D
P2860
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Development and characterizati ...... cine for grass pollen allergy.
@ast
Development and characterizati ...... cine for grass pollen allergy.
@en
type
label
Development and characterizati ...... cine for grass pollen allergy.
@ast
Development and characterizati ...... cine for grass pollen allergy.
@en
prefLabel
Development and characterizati ...... cine for grass pollen allergy.
@ast
Development and characterizati ...... cine for grass pollen allergy.
@en
P2093
P2860
P50
P1476
Development and characterizati ...... ccine for grass pollen allergy
@en
P2093
Angela Neubauer
Bernhard Maderegger
Frank Stolz
Gottfried Stegfellner
Hans Huber
Josef Thalhamer
Katarzyna Niespodziana
Katharina Blatt
Katharina Marth
Margarete Focke-Tejkl
P2860
P304
1207-7.e1-11
P356
10.1016/J.JACI.2014.09.012
P407
P577
2014-11-13T00:00:00Z